BLTEBelite BioBLTE info
$48.42info-0.10%24h
Global rank6596
Market cap$1.34B
Change 7d0.48%
YTD Performance5.88%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Belite Bio (BLTE) Stock Overview

    Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

    BLTE Stock Information

    Symbol
    BLTE
    Address
    12750 High Bluff DriveSan Diego, CA 92130United States
    Founded
    -
    Trading hours
    -
    Website
    https://belitebio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 246 6240

    Belite Bio (BLTE) Price Chart

    -
    Value:-

    Belite Bio Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $48.42
    N/A
    Market Cap
    $1.34B
    N/A
    Shares Outstanding
    27.60M
    N/A
    Employees
    16.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org